Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc., 26926 [2024-07988]

Download as PDF 26926 Federal Register / Vol. 89, No. 74 / Tuesday, April 16, 2024 / Notices antitrust plaintiffs to actual damages under specified circumstances. Specifically, NFPA has provided an updated and current list of its standards development activities and related technical committee and conformity assessment activities. Information concerning NFPA regulations, technical committees, current standards, standards development, and conformity assessment activities are publicly available at nfpa.org. On September 20, 2004, NFPA filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on October 21, 2004 (69 FR 61869). The last notification was filed with the Department on October 2, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on December 15, 2023 (88 FR 86937). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2024–07993 Filed 4–15–24; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Antitrust Division khammond on DSKJM1Z7X2PROD with NOTICES Notice Pursuant to the National Cooperative Research and Production Act of 1993—UHD Alliance, Inc. Notice is hereby given that, on January 25, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), UHD Alliance, Inc. (‘‘UHD Alliance’’) filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Qualcomm Incorporated, San Diego, CA; and Formovie (Chongqing) Innovative Technology Co., Ltd., Beijing, PEOPLE’S REPUBLIC OF CHINA have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and UHD Alliance intends to file additional written notifications disclosing all changes in membership. VerDate Sep<11>2014 19:09 Apr 15, 2024 Jkt 262001 On June 17, 2015, UHD Alliance filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on July 17, 2015 (80 FR 42537). The last notification was filed with the Department on August 30, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on October 6, 2023(88 FR 69673). The last notification was filed with the Department on June 23, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on August 23, 2023 (88 FR 57479). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. DEPARTMENT OF JUSTICE Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2024–07988 Filed 4–15–24; 8:45 am] BILLING CODE P Antitrust Division [FR Doc. 2024–07938 Filed 4–15–24; 8:45 am] Notice Pursuant to the National Cooperative Research and Production Act of 1993—Bytecode Alliance Foundation BILLING CODE P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Subcutaneous Drug Development & Delivery Consortium, Inc. Notice is hereby given that on February 2, 2024, pursuant to section 6(a) of the Act of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Subcutaneous Drug Development & Delivery Consortium, Inc. (‘‘SC Consortium’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Eli Lilly and Company, Indianapolis, IN; and Kale´o, Inc., Richmond, VA, have withdrawn as parties to this venture. No other changes have been made in the membership or the planned activity of the group research project. Membership in this group research project remains open and Subcutaneous Drug Development & Delivery Consortium, Inc. intends to file additional written notifications disclosing all changes in membership. On October 26, 2020, Subcutaneous Drug Development & Delivery Consortium, Inc. filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on December 3, 2020 (85 FR 78148). PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 Notice is hereby given that, on March 14, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Bytecode Alliance Foundation has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, JAF Labs, Austin, TX, has been added as a party to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Bytecode Alliance Foundation intends to file additional written notifications disclosing all changes in membership. On April 20, 2022, Bytecode Alliance Foundation filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to section 6(b) of the Act on May 13, 2022 (87 FR 29379). The last notification was filed with the Department on October 3, 2023. A notice was published in the Federal Register pursuant to section 6(b) of the Act on December 15, 2023 (88 FR 86936). Suzanne Morris, Deputy Director Civil Enforcement Operations, Antitrust Division. [FR Doc. 2024–07989 Filed 4–15–24; 8:45 am] BILLING CODE P E:\FR\FM\16APN1.SGM 16APN1

Agencies

[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Page 26926]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07988]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that on February 2, 2024, pursuant to 
section 6(a) of the Act of the National Cooperative Research and 
Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), 
Subcutaneous Drug Development & Delivery Consortium, Inc. (``SC 
Consortium'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Eli Lilly and Company, Indianapolis, IN; and 
Kal[eacute]o, Inc., Richmond, VA, have withdrawn as parties to this 
venture.
    No other changes have been made in the membership or the planned 
activity of the group research project. Membership in this group 
research project remains open and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on June 23, 
2023. A notice was published in the Federal Register pursuant to 
section 6(b) of the Act on August 23, 2023 (88 FR 57479).

Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07988 Filed 4-15-24; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.